STAT

FEBRUARY 1, 2024

WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. The Biden administration will publish the final prices by Sept. And that’s about all they said.

Drug Pricing 331

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 331

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 239

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 239

pharmaphorum

JUNE 2, 2022

In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

STAT

MARCH 7, 2024

— Pharma industry giants including Bristol Myers Squibb, Johnson and Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

Drug Pricing 347

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 347

STAT

FEBRUARY 1, 2024

… The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, but declined to disclose any details , STAT tells us. Companies have until March 2 to either accept the government’s offer or propose a counteroffer.

Drug Pricing 259

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 259

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

This could evolve into pharmaceutical companies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52